Author

Hilda Giugno

Observed name: H. Giugno

Institution: Garrahan Hospital

Observed institutions: University of Kentucky, Garrahan Hospital

ORCID: 0000-0002-0681-211X

Observed ORCID: 0000-0002-0681-211X

OpenAlex ID: A5018045695

Mannose-binding lectin gene as a modifier of the cystic fibrosis phenotype in Argentinean pediatric patients

2014 · Luis Pablo Gravina, Carolina Crespo, et al. · Journal of Cystic Fibrosis · 16

PDF

[Effect of oximetry on hospitalization in bronchiolitis. a randomized clinical trial].

2015 · Hilda Giugno · PubMed · 9

[Validation of a clinical prediction tool to evaluate severity in children with wheezing].

2010 · Alejandra Coarasa, Hilda Giugno, et al. · PubMed · 6

WS3.5 Inhaled 7% hypertonic saline treatment in preschool children with cystic fibrosis

2014 · S. Palacio, H. Giugno, et al. · Journal of Cystic Fibrosis · 4

PDF

[Early antibiotic treatment for eradication of initial infection by Pseudomonas aeruginosa in patients with cystic fibrosis].

2010 · Hilda Giugno, Claudio Castaños, et al. · PubMed · 2

Clinical and functional course of patients with cystic fibrosis treated with lumacaftor/ivacaftor at a children’s hospital. A case series

2023 · M Sol Fernández Sardá, Lourdes Báez Mellid, et al. · Archivos Argentinos de Pediatria · 1

PDF

Real-world experience with a generic formulation of elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis

2026 · María Macarena Oneglia, Hilda Giugno, et al. · Journal of Cystic Fibrosis

844 Train-The-Trainer model to improve cystic fibrosis care in resource- limited countries

2025 · K. Plubatsch, H. Giugno, et al. · Journal of Cystic Fibrosis

846 Implementation and sustainability of QI-focused management of CF care in low-resource settings

2025 · H. Giugno, M. Plubatsch, et al. · Journal of Cystic Fibrosis

P055 Real‐life experience with a generic formulation of elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis

2024 · M.M. Oneglia, H. Giugno, et al. · Journal of Cystic Fibrosis

536 Effect of elexacaftor-tezacaftor-ivacaftor on nutritional status and glucose metabolism in children and adolescents with cystic fibrosis

2023 · A. Agustinho, M. Araujo, et al. · Journal of Cystic Fibrosis

PDF

666 Impact of effective cystic fibrosis center team training in a low- to middle-income country

2023 · C. Castaños, M. Plubatsch, et al. · Journal of Cystic Fibrosis

PDF

WS21.04 Molecular characterisation of the CFTR gene in the Argentinian population: impact of local variants in the sensitivity of genetic testing

2022 · C. Crespo, H. Giugno, et al. · Journal of Cystic Fibrosis

P106 Prevalence of methicillin-resistant Staphylococcus aureus and its eradication in paediatric cystic fibrosis patients

2019 · C.M. Morales, H. Giugno, et al. · Journal of Cystic Fibrosis

ePS2.07 Treatment of hemoptysis in patients with cystic fibrosis: embolisation

2019 · C.M. Morales, V. Padula, et al. · Journal of Cystic Fibrosis

P057 Outcomes post transitional from a paediatric to an adult cystic fibrosis centre in Argentina

2019 · E. Baran, C. Castaños, et al. · Journal of Cystic Fibrosis

P010 In the era of CFTR modulators, does newborn screening detect cystic fibrosis patients with residual function mutations?

2019 · C. Crespo, H. Giugno, et al. · Journal of Cystic Fibrosis

PDF

Series de Pediatría Garrahan. El niño con problemas respiratorios

2018 · Claudio Castaños, Pedro Rino, et al.

13 Mannose binding lectin gene as a modifier of cystic fibrosis phenotype in Argentinian pediatric patients

2012 · C. Crespo, H. Giugno, et al. · Journal of Cystic Fibrosis

PDF

Works count: 19

Citation count: 38

H-index: 4

I10-index: 1